secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2023-10-13T23:59:59+00:00
Accession:  0001104659-23-108983
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS expects REGAL enrollment ex-China by Nov 2023; China start triggers $13M milestone
--------------------------------------------------------------------------------

- Enrollment outside China expected to complete in November 2023; patient numbers for interim and final analyses already enrolled.
- Interim analysis (60 events) on track for late 2023/early 2024; final analysis (80 events) targeted by end of 2024.
- China partner 3D Medicines to begin REGAL enrollment in Q4 2023, triggering two milestone payments totaling $13.0 million.
- 3D Medicines has obtained all regulatory permits and set up 11 treatment centers in China; previously projected Q3 start delayed by supply-chain issues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000110465923108983/0001104659-23-108983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000110465923108983/tm2328393d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-108983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer